IMMvention Therapeutix, Inc. Email Format
Biotechnology ResearchNorth Carolina, United States11-50 Employees
Venture-funded company, discovering and developing oral novel small molecule first-in-class inhibitors of Bach1 (a transcription factor) as transformative potential therapy, globally accessible for patients with sickle cell disease (SCD), renal, cardiometabolic and neurodegenerative and other diseases.